Article ISI
LANCET ONCOLOGY  (2021)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; Lingua, Alejo; Souquet, Pierre-Jean; De Marchi, Pedro; Martin, Claudio; Perol, Maurice; et. al.

Abstract

Background First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit.

Más información

Título según WOS: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Título de la Revista: LANCET ONCOLOGY
Volumen: 22
Número: 2
Editorial: Elsevier Science Inc.
Fecha de publicación: 2021
Página de inicio: 198
Página final: 211
DOI:

10.1016/S1470-2045(20)30641-0
Notas: ISI